IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV

Group 1 - The DJS Law Group is reminding investors of a class action lawsuit against Iovance Biotherapeutics, Inc. for violations of federal securities laws [1] - Shareholders who purchased Iovance's securities between May 9, 2024, and May 8, 2025, are encouraged to contact the firm before July 14, 2025 [1] - The lawsuit alleges that Iovance made false and misleading statements regarding the timelines for treatment with Amtagvi and the effectiveness of its sales team and Authorized Treatment Centers [2] Group 2 - The complaint indicates that the failure to effectively select patients for Amtagvi led to patient drop-off, resulting in lower revenues and higher costs for the company [2] - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns [4]